Alumis Inc (ALMS)

$3.60 +0.08 (2.27%)
Market Cap 191.51M
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 697,800
Avg Vol 931,758
Day's Range N/A - N/A
Shares Out 54.41M
Stochastic %K 86%
Beta N/A
Analysts Strong Sell
Price Target $21.00

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
777Dog
777Dog Jul. 15 at 1:03 PM
$ALMS Five (5) analysts with average target $20...AI says: It is extremely rare for analysts to project a 500%+ increase in a share price over the next year. Such a projection would indicate a massive, and highly unusual, surge in value for a publicly traded company. Typically, analyst price targets involve more modest percentage increases or decreases, reflecting a more realistic assessment of a company's potential growth and market conditions. While there might be instances where a small or emerging company's stock is expected to see a substantial percentage increase, these are usually outliers and often accompanied by significant risk factors. Therefore, while it's possible to find isolated cases of analysts predicting extreme price movements, it is highly unusual and not representative of typical market expectations.
0 · Reply
777Dog
777Dog Jul. 14 at 8:32 PM
$ALMS Is Sanofi smelling our tail...perhaps...perplexity says they like to buy firms and they now identify as AI... In 2025, Sanofi is ranked as the eighth largest pharmaceutical company globally, with 2023 sales of approximately $46.2 billion. Sanofi actively makes acquisitions to strengthen its portfolio and pipeline. In 2025, Sanofi agreed to acquire the U.S.-based biopharma company Blueprint Medicines for up to $9.5 billion, marking its largest deal in seven years. The $470 million purchase of Vigil Neuroscience, focused on Alzheimer's disease candidates The $2.2 billion acquisition of Inhibrx, a biotech specializing in rare disease drugs The acquisition of DR-0201, a bispecific antibody from Dren Bio Sanofi’s CEO Paul Hudson has stated the company retains a "sizeable capacity for further acquisitions," emphasizing that M&A is a key part of its growth and innovation strategy
0 · Reply
777Dog
777Dog Jul. 14 at 8:22 PM
$ALMS I am liking this...Sanam promoted...Acelyrin merge going well and she has quite a pedigree with considerable M&A experience... Is something brewing to explain why they are so quiet...who knows... "Prior to joining Alumis in September 2024, Sanam served in various leadership roles at ACELYRIN, Inc., most recently as Chief Legal Officer and Head of People. She previously held senior legal roles at companies across the biopharmaceutical, technology, and renewable energy industries—including General Counsel at Snapdocs, Inc. and Associate General Counsel at Principia Biopharma through its acquisition by Sanofi. Sanam began her legal career in the Business & Finance practice group at Morrison & Foerster LLP, advising clients on financing, M&A, securities and corporate governance matters. She holds a J.D. from the University of Pennsylvania Carey Law School and a B.A. in Political Science from UC San Diego"
0 · Reply
DCRMIA
DCRMIA Jul. 14 at 5:54 PM
Things are going well with $ALMS , but not as amazing as I hoped. $10 by September, let's go!🚀🚀
0 · Reply
777Dog
777Dog Jul. 12 at 12:32 AM
$ALMS this wont hurt...cannot find this one other than this link... U.S. Patent and Trademark Office Awards Patent for Substituted 1,2,4-triazoles as TYK2 Inhibitors Pharmaceutical | Thu 10 Jul 2025 Alexandria, July 11 -- U.S. Patent and Trademark Office has awarded a patent to Alumis Inc for substituted 1,2,4-triazoles as TYK2 inhibitors. Jin Bohan, Dong Qing, Hung Gene and Kaldor Stephen W developed the invention. The patent application number is US202318335262 20230615. The patent publication number is US12351572 (B2).. https://www.globalipnews.com/?industry=Pharmaceutical&key=1W
0 · Reply
777Dog
777Dog Jul. 11 at 5:23 PM
$ALMS AI summary of A-005 reported last December ($9 a share at that time): "Alumis has reported positive outcomes from its Phase 1 clinical trial for A-005, a CNS-penetrant allosteric TYK2 inhibitor. The study involved 135 healthy participants and assessed the drug's safety, tolerability, and pharmacokinetics. A-005 was found to be well tolerated with no serious adverse events. The trial demonstrated that A-005 can cross the blood-brain barrier and achieve significant levels in the cerebral spinal fluid. The drug exhibited dose-proportional increases in exposure and rapid peak concentration. A relationship between pharmacokinetics and pharmacodynamics was established, showing inhibition of TYK2. Alumis states that A-005 is the first reported allosteric TYK2 inhibitor to show human blood-brain barrier penetration for addressing CNS inflammation. Based on these results, Alumis intends to begin a Phase 2 trial of A-005 for multiple sclerosis patients in the latter half of 2025. "
0 · Reply
777Dog
777Dog Jul. 11 at 4:39 PM
$ALMS all they need now is catalyst...we need to wait a few more months for ESK-001data to confirm better than Sotyktu (2024 Sales: $246 million), but A-005 Phase 2 announcement midyear might be next week...who knows? AI: Could Alumis' A-005 affect Alzheimer's Disease? "While Alumis is initially developing A-005 for multiple sclerosis (MS) and Parkinson's Disease, its mechanism of action and preclinical data suggest it could potentially have an impact on Alzheimer's disease (AD). "
0 · Reply
777Dog
777Dog Jul. 11 at 1:44 PM
$ALMS The volume spike will come. It looks like the "club the baby seals" Algo is being changed into a "is anybody out there" Algo... Look at the many jobs they are advertising..they are setting the table for a drug launch and nationwide marketing...Foresite needs a win...$ALMS will deliver their first drug to market...that will be their first big AI Pharma win...the CNS drug will be even bigger IF it has any effect on MS...and even bigger IF it touches Alzheimers with no toxicity... Risk here is obvious, but downside is disappearing after the beating that it has endured. Upside enormous. The volume spike will come...
0 · Reply
777Dog
777Dog Jul. 10 at 10:45 AM
$ALMS The data must look good...they are putting the pieces in place for a drug launch... "Prior experience in helping to develop medical strategic and tactical plans in support of drug launch is highly preferred" https://www.linkedin.com/jobs/view/associate-director-medical-affairs-at-biospace-4263272297
0 · Reply
DCRMIA
DCRMIA Jul. 9 at 10:59 PM
$ALMS very bullish
0 · Reply
Latest News on ALMS
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 18 hours ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 6 weeks ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 6 weeks ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 7 weeks ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 2 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 2 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 3 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 3 months ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 3 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 3 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 3 months ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 4 months ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 4 months ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 4 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 4 months ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 4 months ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 4 months ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 4 months ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 4 months ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 5 months ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 5 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 5 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 6 months ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 8 months ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Oct 17, 2024, 2:32 PM EDT - 9 months ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 10 months ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 10 months ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 10 months ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis to Participate in Upcoming September Investor Conferences

Sep 3, 2024, 4:29 PM EDT - 11 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 11 months ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 24, 2024, 3:18 PM EDT - 1 year ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

Jul 1, 2024, 11:51 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

AGH INHI LB LINE TBN TWFG WBTN

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Jun 28, 2024, 1:36 PM EDT - 1 year ago

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 1 year ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 1 year ago

Alumis Announces Pricing of Initial Public Offering

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 8:27 AM EDT - 1 year ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 1 year ago

Alumis eyes $300 million in proceeds in IPO

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

Jun 11, 2024, 12:25 PM EDT - 1 year ago

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

777Dog
777Dog Jul. 15 at 1:03 PM
$ALMS Five (5) analysts with average target $20...AI says: It is extremely rare for analysts to project a 500%+ increase in a share price over the next year. Such a projection would indicate a massive, and highly unusual, surge in value for a publicly traded company. Typically, analyst price targets involve more modest percentage increases or decreases, reflecting a more realistic assessment of a company's potential growth and market conditions. While there might be instances where a small or emerging company's stock is expected to see a substantial percentage increase, these are usually outliers and often accompanied by significant risk factors. Therefore, while it's possible to find isolated cases of analysts predicting extreme price movements, it is highly unusual and not representative of typical market expectations.
0 · Reply
777Dog
777Dog Jul. 14 at 8:32 PM
$ALMS Is Sanofi smelling our tail...perhaps...perplexity says they like to buy firms and they now identify as AI... In 2025, Sanofi is ranked as the eighth largest pharmaceutical company globally, with 2023 sales of approximately $46.2 billion. Sanofi actively makes acquisitions to strengthen its portfolio and pipeline. In 2025, Sanofi agreed to acquire the U.S.-based biopharma company Blueprint Medicines for up to $9.5 billion, marking its largest deal in seven years. The $470 million purchase of Vigil Neuroscience, focused on Alzheimer's disease candidates The $2.2 billion acquisition of Inhibrx, a biotech specializing in rare disease drugs The acquisition of DR-0201, a bispecific antibody from Dren Bio Sanofi’s CEO Paul Hudson has stated the company retains a "sizeable capacity for further acquisitions," emphasizing that M&A is a key part of its growth and innovation strategy
0 · Reply
777Dog
777Dog Jul. 14 at 8:22 PM
$ALMS I am liking this...Sanam promoted...Acelyrin merge going well and she has quite a pedigree with considerable M&A experience... Is something brewing to explain why they are so quiet...who knows... "Prior to joining Alumis in September 2024, Sanam served in various leadership roles at ACELYRIN, Inc., most recently as Chief Legal Officer and Head of People. She previously held senior legal roles at companies across the biopharmaceutical, technology, and renewable energy industries—including General Counsel at Snapdocs, Inc. and Associate General Counsel at Principia Biopharma through its acquisition by Sanofi. Sanam began her legal career in the Business & Finance practice group at Morrison & Foerster LLP, advising clients on financing, M&A, securities and corporate governance matters. She holds a J.D. from the University of Pennsylvania Carey Law School and a B.A. in Political Science from UC San Diego"
0 · Reply
DCRMIA
DCRMIA Jul. 14 at 5:54 PM
Things are going well with $ALMS , but not as amazing as I hoped. $10 by September, let's go!🚀🚀
0 · Reply
777Dog
777Dog Jul. 12 at 12:32 AM
$ALMS this wont hurt...cannot find this one other than this link... U.S. Patent and Trademark Office Awards Patent for Substituted 1,2,4-triazoles as TYK2 Inhibitors Pharmaceutical | Thu 10 Jul 2025 Alexandria, July 11 -- U.S. Patent and Trademark Office has awarded a patent to Alumis Inc for substituted 1,2,4-triazoles as TYK2 inhibitors. Jin Bohan, Dong Qing, Hung Gene and Kaldor Stephen W developed the invention. The patent application number is US202318335262 20230615. The patent publication number is US12351572 (B2).. https://www.globalipnews.com/?industry=Pharmaceutical&key=1W
0 · Reply
777Dog
777Dog Jul. 11 at 5:23 PM
$ALMS AI summary of A-005 reported last December ($9 a share at that time): "Alumis has reported positive outcomes from its Phase 1 clinical trial for A-005, a CNS-penetrant allosteric TYK2 inhibitor. The study involved 135 healthy participants and assessed the drug's safety, tolerability, and pharmacokinetics. A-005 was found to be well tolerated with no serious adverse events. The trial demonstrated that A-005 can cross the blood-brain barrier and achieve significant levels in the cerebral spinal fluid. The drug exhibited dose-proportional increases in exposure and rapid peak concentration. A relationship between pharmacokinetics and pharmacodynamics was established, showing inhibition of TYK2. Alumis states that A-005 is the first reported allosteric TYK2 inhibitor to show human blood-brain barrier penetration for addressing CNS inflammation. Based on these results, Alumis intends to begin a Phase 2 trial of A-005 for multiple sclerosis patients in the latter half of 2025. "
0 · Reply
777Dog
777Dog Jul. 11 at 4:39 PM
$ALMS all they need now is catalyst...we need to wait a few more months for ESK-001data to confirm better than Sotyktu (2024 Sales: $246 million), but A-005 Phase 2 announcement midyear might be next week...who knows? AI: Could Alumis' A-005 affect Alzheimer's Disease? "While Alumis is initially developing A-005 for multiple sclerosis (MS) and Parkinson's Disease, its mechanism of action and preclinical data suggest it could potentially have an impact on Alzheimer's disease (AD). "
0 · Reply
777Dog
777Dog Jul. 11 at 1:44 PM
$ALMS The volume spike will come. It looks like the "club the baby seals" Algo is being changed into a "is anybody out there" Algo... Look at the many jobs they are advertising..they are setting the table for a drug launch and nationwide marketing...Foresite needs a win...$ALMS will deliver their first drug to market...that will be their first big AI Pharma win...the CNS drug will be even bigger IF it has any effect on MS...and even bigger IF it touches Alzheimers with no toxicity... Risk here is obvious, but downside is disappearing after the beating that it has endured. Upside enormous. The volume spike will come...
0 · Reply
777Dog
777Dog Jul. 10 at 10:45 AM
$ALMS The data must look good...they are putting the pieces in place for a drug launch... "Prior experience in helping to develop medical strategic and tactical plans in support of drug launch is highly preferred" https://www.linkedin.com/jobs/view/associate-director-medical-affairs-at-biospace-4263272297
0 · Reply
DCRMIA
DCRMIA Jul. 9 at 10:59 PM
$ALMS very bullish
0 · Reply
777Dog
777Dog Jul. 9 at 8:52 PM
$ALMS The slam came at the end of the day...140,000 shares dumped in last 10 minutes...still closed green... this is all becoming too obvious...just let it run already...
1 · Reply
777Dog
777Dog Jul. 9 at 1:50 PM
$ALMS No slam at the open again...and no volume compared to the usual 100K in first few minutes...did they turn off the Algo?
1 · Reply
777Dog
777Dog Jul. 9 at 12:25 PM
$ALMS https://www.linkedin.com/posts/alumis-co_the-alumis-team-is-headed-to-boston-on-tuesday-activity-7347995316014469120-PXS0
0 · Reply
DCRMIA
DCRMIA Jul. 9 at 10:40 AM
$ALMS 📈📈🚀🚀🆙️🆙️
0 · Reply
BluntForceOptions
BluntForceOptions Jul. 8 at 11:56 PM
$KYTX $SLDB $ALMS $IRWD showing solid strength today. Get some. 📈
0 · Reply
777Dog
777Dog Jul. 8 at 9:54 PM
$ALMS I know, I know, too many posts from this dog...looks like not too many on this board...yet... This is from Bay Area in April PNAS...wow, really wow! "Collectively, we have presented data that elucidate a coherent mechanism for the role of TYK2 in regulation of neuroinflammation. We demonstrated central inhibition of TYK2 is required for modulation of EAE pathophysiology. Type I IFN-induced TYK2 signaling pathway is functional within glial cells and selective inhibition can result in a pleiotropic impact that extinguishes the neuroinflammatory program at the embers/source. The mechanisms presented here strengthen the strategy for targeting central TYK2 for treatment of MS." pnas.org/doi/10.1073/pnas.2...
0 · Reply
777Dog
777Dog Jul. 8 at 9:34 PM
$ALMS This is actually pretty exciting stuff...Evidence suggests that Tyrosine Kinase 2 (TYK2) is involved in neurodegenerative diseases. Alumis' A-005 is a potential first-in-class CNS-penetrant allosteric tyrosine kinase 2 (TYK2) inhibitor. *Neuroinflammation and TYK2: TYK2 contributes to this neuroinflammation by mediating the signaling of key pro-inflammatory cytokines. *Alzheimer's Disease (AD) and Tauopathy: TYK2 has been linked to AD through its role in tau pathology. Studies show that TYK2 phosphorylates tau at tyrosine 29, promoting the buildup of insoluble tau aggregates, a characteristic of AD. Additionally, TYK2-mediated phosphorylation of tau can hinder its clearance, worsening tau-related neurodegeneration. *TYK2 plays a role in the neuroinflammatory mechanisms associated with TDP-43 pathology in AD and other neurodegenerative conditions like ALS.
0 · Reply
777Dog
777Dog Jul. 8 at 9:23 PM
$ALMS Our next catalyst will be announcement of a-005 for neurodegenerative diseases...MS Cannot await the announcement...and potentially a partner? Well-known neurodegenerative diseases include: Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Multiple System Atrophy, Spinal Muscular Atrophy, Spinocerebellar Ataxia, Prion diseases, and Frontotemporal Dementia. These conditions are characterized by the progressive degeneration of nerve cells, leading to various neurological symptoms and impairments. Yes, most neurodegenerative diseases have an immune component.
0 · Reply
777Dog
777Dog Jul. 8 at 8:57 PM
$ALMS Interesting article comparing Alumis to Roivant... Why Invest? *Pipeline Catalysts: 2026's Phase 3 readouts for ESK-001 and Phase 2 data for A-005/Lonigutamab are binary events with high upside. *Capital Efficiency: The merger with ACELYRIN and shelf offering ensure Alumis avoids dilution... *Roivant's Blueprint: A proven model—acquire undervalued assets, advance them with biomarker-driven trials, and exit at scale... Investment Takeaways: *Buy the Catalysts: Investors should establish a position ahead of 2026's data readouts... *Focus on Long-Term Value: A successful Phase 3 for ESK-001 or a partnership for A-005 could revalue Alumis at multiples... *Urgency is Key: As Roche, Merck, and BMS vie for late-stage assets, the window to acquire undervalued therapies is narrowing. https://www.ainvest.com/news/alumis-400m-shelf-offering-replicating-roivant-s-playbook-in-biotech-s-golden-age-250710109bcb8453fbba130e/
0 · Reply
Sly15
Sly15 Jul. 8 at 3:01 PM
$ALMS This chart pattern is coiling to spring higher
0 · Reply
777Dog
777Dog Jul. 8 at 2:15 PM
$ALMS The psoriasis treatment market is experiencing significant growth and is projected to reach USD 68.24 billion by 2033, with a compound annual growth rate (CAGR) of 8% from 2024 to 2034. This growth is driven by factors such as increasing prevalence of psoriasis, rising awareness of chronic inflammatory conditions, and the expanding adoption of advanced therapies like biologics and targeted treatments.
0 · Reply
777Dog
777Dog Jul. 8 at 2:13 PM
$ALMS Perplexity: "Based on available phase 2 data, ESK-001 appears to deliver higher rates of skin clearance (PASI 75 and above) than methotrexate, with a comparable or better safety profile. Direct head-to-head trials are needed for definitive comparison, but current evidence suggests ESK-001 could be a more effective oral option for many patients with moderate-to-severe plaque psoriasis" Regarding current FDA approved drugs: "No oral alternative is clearly more effective and less toxic than methotrexate for psoriasis. Apremilast offers a better safety profile but with somewhat lower efficacy. Most other oral agents either have similar or greater toxicity or are less effective. For patients prioritizing safety and tolerability, apremilast is a reasonable alternative, but for maximal skin clearance, methotrexate or cyclosporine may still be preferred, with careful monitoring"
0 · Reply